TB-500: eye-drop research does not prove injury healing

Evidence as of September 2026.

• Shown: thymosin-related preparations have produced laboratory, animal and some clinical signals worth investigating. [1] [2] [14]

• Not shown: that the defined seven-amino-acid TB-500 fragment heals human injuries; FDA found no studies administering the forms it evaluated to people. [1]

• Would change the assessment: a well-controlled human study of that fragment. Pending eye-drop results address the full-length molecule instead. [1] [6]

Which molecule did the study actually test?

TB-500, natural thymosin beta-4 and the heart-treatment candidate NL005 are different molecules. Their names are often grouped together in healing claims, but their evidence cannot be combined into one treatment record. [1] [11]

Natural thymosin beta-4 contains 43 amino acids. The TB-500 in FDA’s 2026 evaluation is a seven-amino-acid fragment with an attached chemical group, called acetylation. The eye drops RGN-259 contain full-length thymosin beta-4. NL005 is a distinct, 44-amino-acid product made using genetically modified cells. [1] [2] [11]

The difference is more than length: changing the chain can change its behavior and breakdown. The unacetylated fragment is another distinct form; FDA’s free-base/acetate-salt distinction is separate from acetylation. Readers do not need to memorize the chemistry, but they do need the exact preparation before interpreting a result. [1]

What did the eye trials find?

SEER-1 produced an encouraging signal but missed its planned main test. The trial studied a specific condition in which nerve damage prevents the cornea, the eye’s clear front surface, from healing normally. It planned 46 participants but stopped at 18 because recruitment was slow. [2]

The primary endpoint is the main outcome a trial chooses in advance. In SEER-1, the day-29 comparison did not meet the usual threshold for statistical significance. A later assessment favored the drops, but a favorable secondary result does not replace the main test. The placebo group was also older and had larger defects at the start. An alternative analysis violated a sample-size assumption. [2]

SEER-1 recorded 16 adverse events across seven people: 11 events in four treated participants and five in three placebo participants. One treated-group event was classed as treatment-related; a separate serious event was judged unrelated. The study was funded by ReGenTree and included company-linked authors. [2]

HLB Therapeutics reported in June 2025 that SEER-3 missed its primary endpoint. Its explanation of unexpectedly high placebo healing is a company interpretation. In September 2025, HLB said it was withholding detailed numerical results while SEER-2 continued, leaving the full findings and harms unavailable for independent appraisal. [12] [13]

Does the fragment help tendons?

The fragment’s human effect is unknown, and the animal evidence contains an identity problem. A 2026 study found stronger repaired Achilles tendons in rats given a commercial product called TB-500, but did not publish its amino-acid sequence. Only four tendons per group underwent mechanical testing; functional recovery was not assessed. Combining the product with BPC-157 gave no additional advantage. [14]

In a 2024 laboratory experiment, the defined TB-500 fragment did not significantly improve closure of a gap in a layer of connective-tissue cells. A smaller breakdown product did. That single assay does not prove the fragment fails everywhere, but it challenges the assumption that the parent molecule’s effects automatically carry over. Experiments with human serum in the same research were performed outside the body, not in treated patients. [1] [5]

What are the risks and regulatory limits?

Human safety information for the fragment is inadequate. FDA highlights possible immune responses related to impurities and clumping of peptide molecules. A purity claim cannot show that a product improves recovery or that repeated injections are acceptably safe. [7]

The July 2026 US advisory materials concerned pharmacy preparation of defined TB-500 forms for wound healing. Such consideration is not approval of a finished medicine, and committee advice does not bind FDA. A January 20, 2026 FDA warning letter identified GenoGenix’s thymosin beta-4 products as unapproved; the letter concerned those products, not every research program. [1] [4] [8]

What should we watch next?

The next useful milestones are full results for specific products, with harms reported alongside healing.

• SEER-2: HLB’s August 26, 2026 notice expected initial results in mid-November. That was a company timetable, not a reported benefit. [6]

• SEER-3: publication of the complete results would clarify the missed primary endpoint and safety findings. Detailed numbers were withheld in the September 2025 notice. [13]

• NL005: the 90-person phase 2b registry record described completion without posted results; a May 14, 2026 phase 2c record planned 189 people and had not started recruiting. Both study heart-muscle injury after heart attack, not TB-500 for tendons. [3] [10] [11]

How Healthy Longevity Clinic experts evaluate the evidence

Healthy Longevity Clinic puts product identity before a healing claim. In this case, that means separating the full thymosin beta-4 molecule from the shorter TB-500 fragment, then checking the route of administration and the tissue being treated. An eye-drop result cannot fill the evidence gap for an injection intended to heal a tendon.

The clinical studies also deserve their own careful reading: the small SEER-1 trial produced an encouraging later result after missing its main statistical test. That is a reason to investigate further, not to carry the benefit across to a different compound. Direct human results for the identified fragment would change the assessment.

This gives you a practical way to evaluate an offer. Ask to see the trial that tested the exact product for the exact problem you want treated. A closely related name or a plausible repair mechanism does not complete that chain of evidence.

Three questions for a treatment discussion

1. Is the cited study about the seven-amino-acid fragment, full-length thymosin beta-4 or NL005?

2. Did it measure human recovery, eye-surface closure, or only a laboratory or animal outcome?

3. Did the trial meet its planned main goal, and where are its complete results and harms?

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

Not in the FDA evaluation discussed here. TB-500 is an acetylated seven-amino-acid fragment; natural thymosin beta-4 has 43 amino acids. Loose use of the name online can obscure that distinction. [1]

Do the eye-drop trials prove TB-500 heals injuries?

No. They tested full-length thymosin beta-4 in a specific eye condition, and the reported main results were not clearly positive. They did not test injections of the fragment for tendon or muscle injuries. [2] [12]

Has TB-500 been tested in people?

FDA’s 2026 assessment found no studies in which people received the TB-500 forms it evaluated. Human studies of related preparations should be identified by their own names. [1]